Cleo Diagnostics (COV:AU) has announced CLEO Further Expands Ovarian Cancer Trial with Siles Health Download the PDF here. This post appeared first on investingnews.com Prev Post Completion of preclinical data package for RAD 402 December 10, 2024 Next Post Nauru agrees to give Australia veto rights overpacts with third nations including China December 10, 2024 Related Posts 5 Best-performing Junior Copper Stocks on the TSXV in 2024 December 24, 2024 Cannabis Market 2024 Year-End Review December 24, 2024 Lode Gold Announces $350,000 Non-Brokered Financing December 24, 2024